{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-011854","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2022-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.217303+00:00","generated_at":"2026-06-26T23:40:26.311798+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"William Lis steps down as CEO; Ronald Martell appointed President and CEO; Lis becomes Chairperson","bullets":["William Lis terminates employment as CEO effective March 15, 2022; remains as Class III director and non-employee Chairperson for 12-month term.","As Chairperson, Lis receives $250,000 annual fee; after board service, consulting at $12,250/month through later of 12 months or March 15, 2024.","Lis will be granted option to purchase 100,000 shares of common stock, vesting monthly over 12 months commencing March 15, 2022.","Prior employment agreement and severance plan terminated; if terminated without Cause, Lis receives continued annual fee and full option vesting.","Ronald Martell appointed as President and CEO; specific compensation terms for Martell not disclosed in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-011854","json":"https://secwatch.observer/filing/0001213900-22-011854.json","markdown":"https://secwatch.observer/filing/0001213900-22-011854.md","text":"https://secwatch.observer/filing/0001213900-22-011854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/ea156711-8k_jasperther.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:40:26.311798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27c162d8fa","claim":"William Lis was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..","evidence_excerpt":"Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"commenced serving"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"5e9b7fbf76","claim":"Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..","evidence_excerpt":"On March 7, 2022, in connection with the appointment of Ronald Martell as the President and Chief Executive Officer of Jasper Therapeutics, Inc. (the “Company”),","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ef75fb1ea2","claim":"William Lis was terminated as Chief Executive Officer at Jasper Therapeutics, Inc..","evidence_excerpt":"Mr. Lis’ employment with the Company will terminate as of March 15, 2022, at which time, Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}